Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Intravenous iron dose and mortality in hemodialysis patients.

Goodkin DA, Bailie GR.

Kidney Int. 2015 Jun;87(6):1261-2. doi: 10.1038/ki.2015.82. No abstract available.

2.

Intravenous iron, inflammation, and ventricular dysfunction during hemodialysis.

Goodkin DA, Bailie GR.

Am J Kidney Dis. 2015 Mar;65(3):518. doi: 10.1053/j.ajkd.2014.09.030. No abstract available.

PMID:
25704045
3.

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.

Kidney Int. 2015 Jan;87(1):162-8. doi: 10.1038/ki.2014.275. Epub 2014 Jul 30.

4.

Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.

Nephrol Dial Transplant. 2013 Oct;28(10):2570-9. doi: 10.1093/ndt/gft062.

PMID:
24078642
5.

Oxidative effect of several intravenous iron complexes in the rat.

Bailie GR, Schuler C, Leggett RE, Li H, Li HD, Patadia H, Levin R.

Biometals. 2013 Jun;26(3):473-8. doi: 10.1007/s10534-013-9632-4. Epub 2013 May 17.

PMID:
23681275
6.

Management of iron deficiency and anemia after Roux-en-Y gastric bypass surgery: an observational study.

Malone M, Alger-Mayer S, Lindstrom J, Bailie GR.

Surg Obes Relat Dis. 2013 Nov-Dec;9(6):969-74. doi: 10.1016/j.soard.2013.01.019. Epub 2013 Feb 13.

PMID:
23499191
7.

Adverse events associated with intravenous iron preparations: a comparison of reported rates.

Bailie GR.

Clin Adv Hematol Oncol. 2012 Sep;10(9):600-2. No abstract available.

PMID:
23073127
8.
9.

Comparison of rates of reported adverse events associated with i.v. iron products in the United States.

Bailie GR.

Am J Health Syst Pharm. 2012 Feb 15;69(4):310-20. doi: 10.2146/ajhp110262.

PMID:
22302256
10.

Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America.

Bailie GR, Hörl WH, Verhoef JJ.

Arzneimittelforschung. 2011;61(5):267-75. doi: 10.1055/s-0031-1296198.

PMID:
21755809
11.

Quantifying home medication regimen changes and quality of life in patients receiving nocturnal home hemodialysis.

Cardone KE, Manley HJ, Grabe DW, Meola S, Hoy CD, Bailie GR.

Hemodial Int. 2011 Apr;15(2):234-42. doi: 10.1111/j.1542-4758.2011.00539.x. Epub 2011 Mar 13.

PMID:
21395973
12.
13.

Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Bailie GR, Mason NA, Valaoras TG.

Hemodial Int. 2010 Jan;14(1):47-54. doi: 10.1111/j.1542-4758.2009.00409.x. Epub 2009 Nov 3.

14.

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK.

J Am Soc Nephrol. 2009 May;20(5):1094-101. doi: 10.1681/ASN.2008060579. Epub 2009 Apr 8.

15.

Erythropoietin effectiveness index : a quantitative definition of resistance in haemodialysis patients with adequate iron stores.

Bailie GR, Low CL, Eisele G.

Clin Drug Investig. 1998;15(1):57-60. No abstract available.

PMID:
18370466
16.

A project management approach to an ACPE accreditation self-study.

Dominelli A, Iwanowicz SL, Bailie GR, Clarke DW, McGraw PS.

Am J Pharm Educ. 2007 Apr 15;71(2):23.

17.

Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).

Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW.

Am J Kidney Dis. 2007 Mar;49(3):426-31.

PMID:
17336704
18.

Sexual dysfunction in dialysis patients treated with antihypertensive or antidepressive medications: results from the DOPPS.

Bailie GR, Elder SJ, Mason NA, Asano Y, Cruz JM, Fukuhara S, Lopes AA, Mapes DL, Mendelssohn DC, Bommer J, Young EW.

Nephrol Dial Transplant. 2007 Apr;22(4):1163-70. Epub 2007 Feb 1.

PMID:
17284436
19.

Iron and the anaemia of chronic disease: a review and strategic recommendations.

Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K.

Curr Med Res Opin. 2006 Apr;22(4):731-7. Review.

20.

Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Bailie GR, Mason NA, Elder SJ, Andreucci VE, Greenwood RN, Akiba T, Saito A, Bragg-Gresham JL, Gillespie BW, Young EW.

Hemodial Int. 2006 Apr;10(2):180-8.

21.

Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.

Bailie GR, Massry SG; National Kidney Foundation.

Pharmacotherapy. 2005 Dec;25(12):1687-707. Review.

PMID:
16305288
22.

Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients.

Elwell RJ, Manley HJ, Frye RF, Bailie GR.

Int J Artif Organs. 2005 Aug;28(8):808-16.

PMID:
16211531
23.

Medication-related problems in ambulatory hemodialysis patients: a pooled analysis.

Manley HJ, Cannella CA, Bailie GR, St Peter WL.

Am J Kidney Dis. 2005 Oct;46(4):669-80.

PMID:
16183422
24.

Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis.

Elwell RJ, Frye RF, Bailie GR.

Perit Dial Int. 2005 Jul-Aug;25(4):380-6.

PMID:
16022096
25.

Analysis of medication use in peritoneal dialysis patients in two units.

Bailie GR, Mason NA, Elwell RJ, Sy FZ.

Perit Dial Int. 2005 May-Jun;25(3):287-90. No abstract available.

PMID:
15981778
26.

Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease.

Bailie GR, Uhlig K, Levey AS.

Pharmacotherapy. 2005 Apr;25(4):491-502. Review.

PMID:
15977910
27.

Hypersensitivity reactions and deaths associated with intravenous iron preparations.

Bailie GR, Clark JA, Lane CE, Lane PL.

Nephrol Dial Transplant. 2005 Jul;20(7):1443-9. Epub 2005 Apr 26.

PMID:
15855210
28.

Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.

Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group.

Nephron Clin Pract. 2005;100(3):c55-62. Epub 2005 Apr 11.

PMID:
15824508
29.

Therapeutic dilemmas in the management of peritonitis.

Bailie GR.

Perit Dial Int. 2005 Mar-Apr;25(2):152-6. Review. No abstract available.

PMID:
15796142
30.

Peritoneal dialysis-related infections recommendations: 2005 update.

Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L; ISPD Ad Hoc Advisory Committee.

Perit Dial Int. 2005 Mar-Apr;25(2):107-31. Review. No abstract available.

PMID:
15796137
31.

Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects.

Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R.

Nephrol Dial Transplant. 2005 Jun;20(6):1110-5. Epub 2005 Mar 15.

PMID:
15769809
32.

HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients.

Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW.

Am J Kidney Dis. 2005 Jan;45(1):119-26.

PMID:
15696451
33.

Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.

Manley HJ, Elwell RJ, Bailie GR, Welch CL.

Ann Pharmacother. 2004 Dec;38(12):2035-40. Epub 2004 Nov 9.

PMID:
15536141
35.

Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription.

Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW.

Kidney Int. 2004 Jun;65(6):2419-25.

36.

Delayed absorption and postdialysis rebound in a case of acute methanol poisoning.

Elwell RJ, Darouian P, Bailie GR, Eisele G, McGoldrick MD.

Am J Emerg Med. 2004 Mar;22(2):126-7. No abstract available.

PMID:
15011234
37.
38.

Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin.

Manley HJ, Bridwell DL, Elwell RJ, Bailie GR.

Perit Dial Int. 2003 Sep-Oct;23(5):469-74.

PMID:
14604200
39.

Hepatitis B vaccination: addressing a drug-related problem in hemodialysis outpatients with a collaborative initiative.

Elwell RJ, Neumann M, Manley HJ, Carpentier L, Bailie GR.

Nephrol Nurs J. 2003 Jun;30(3):310-3.

PMID:
12861899
40.

Gentamicin pharmacokinetics during slow daily home hemodialysis.

Manley HJ, Bailie GR, McClaran ML, Bender WL.

Kidney Int. 2003 Mar;63(3):1072-8.

41.

Treatment of peritonitis in APD: pharmacokinetic principles.

Manley HJ, Bailie GR.

Semin Dial. 2002 Nov-Dec;15(6):418-21. Review.

PMID:
12437537
42.

Safety of propoxyphene in dialysis patients.

Bailie GR, Johnson CA.

Semin Dial. 2002 Sep-Oct;15(5):375. No abstract available.

PMID:
12358644
43.

Comparative review of the pharmacokinetics of vitamin D analogues.

Bailie GR, Johnson CA.

Semin Dial. 2002 Sep-Oct;15(5):352-7. Review.

PMID:
12358640
44.

Analysis of renal bone disease treatment in dialysis patients.

Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S.

Am J Kidney Dis. 2002 Jun;39(6):1270-7.

PMID:
12046041
45.

Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics.

Diaz-Buxo JA, Crawford TL, Bailie GR.

Perit Dial Int. 2001;21 Suppl 3:S197-201. No abstract available.

PMID:
11887820
46.

Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients.

Manley HJ, Bailie GR, Frye RF, McGoldrick MD.

Perit Dial Int. 2001 Jul-Aug;21(4):378-85.

PMID:
11587401
47.

Nutritional markers during peritoneal dialysis: data from the 1998 Peritoneal Dialysis Core Indicators Study.

Flanigan MJ, Frankenfield DL, Prowant BF, Bailie GR, Frederick PR, Rocco MV.

Perit Dial Int. 2001 Jul-Aug;21(4):345-54.

PMID:
11587396
48.

Empiric initial therapy and dose of vancomycin.

Diaz-Buxo JA, Bailie GR.

Perit Dial Int. 2000 Nov-Dec;20(6):829. No abstract available.

PMID:
11405184
49.

Effects of intraperitoneal cefazolin on mesothelial cells in noninfected CAPD patients.

Manley HJ, Bailie GR.

Perit Dial Int. 2001 Jan-Feb;21(1):83-5. No abstract available.

PMID:
11280503
50.

Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.

Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA.

Am J Kidney Dis. 2001 Apr;37(4):766-76. Erratum in: Am J Kidney Dis 2001 May;37(5):1111.

PMID:
11273877

Supplemental Content

Loading ...
Support Center